3/20
08:44 am
ifrx
InflaRx (IFRX) had its price target lowered by Guggenheim from $22.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
InflaRx (IFRX) had its price target lowered by Guggenheim from $22.00 to $14.00. They now have a "buy" rating on the stock.
3/19
07:30 am
ifrx
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Medium
Report
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
3/18
07:30 am
ifrx
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
Medium
Report
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
3/13
05:30 pm
ifrx
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement [Yahoo! Finance]
3/13
05:00 pm
ifrx
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Medium
Report
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
3/12
07:30 am
ifrx
InflaRx to Report Full Year 2025 Results on March 19, 2026
Low
Report
InflaRx to Report Full Year 2025 Results on March 19, 2026
2/26
08:13 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
2/26
07:30 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
1/29
07:30 am
ifrx
InflaRx Announces Participation in February Investor Conferences
Low
Report
InflaRx Announces Participation in February Investor Conferences
1/8
08:00 am
ifrx
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
Medium
Report
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
12/31
12:13 pm
ifrx
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/30
10:54 am
ifrx
InflaRx (NASDAQ:IFRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
InflaRx (NASDAQ:IFRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
12/30
07:30 am
ifrx
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
Medium
Report
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum